Windward Bio Group AG is a clinical-stage biopharmaceutical company focused on the discovery, licensing, and clinical development of differentiated, ultra-long-acting biologic therapeutics targeting clinically validated immunological pathways. The company operates primarily from Basel, Switzerland, with corporate operations also established in the United States, and holds commercialization rights to its clinical-stage assets outside Greater China. Windward Bio operates in a single operating segment focused on research and drug development and is pre-revenue, having generated no commercial product sales since inception. Its pipeline is anchored by two primary clinical assets: WIN378, an ultra-long-acting fully human monoclonal antibody designed to inhibit TSLP, currently being evaluated in a Phase 2/3 study (POLARIS-1) for severe uncontrolled asthma and a Phase 2 study (SIRIUS) for COPD with a target twice-yearly subcutaneous dosing regimen; and WIN027, an investigational long-acting bispecific antibody designed to neutralize both TSLP and IL-13 simultaneously, undergoing Phase 1 evaluation with planned Phase 2 studies in COPD and atopic dermatitis. The company also maintains internal discovery research to feed its pipeline of bispecific antibodies. Windward Bio targets substantial therapeutic markets including severe asthma, COPD, and atopic dermatitis, competing against approved biologic standards of care such as tezepelumab (Tezspire) and dupilumab (Dupixent). Its competitive positioning centers on optimized molecular design aimed at substantially longer dosing intervals (e.g., semi-annual subcutaneous injections) and dual-pathway cytokine inhibition, designed to improve real-world treatment adherence and disease control.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!